Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors

Details for Australian Patent Application No. 2006243218 (hide)

Owner Antisense Pharma GmbH

Inventors Schlingensiepen, Karl-Hermann; Schlingensiepen, Reimar

Agent Davies Collison Cave

Pub. Number AU-B-2006243218

PCT Pub. Number WO2006/117400

Priority 05009802.9 05.05.05 EP; 60/680,493 13.05.05 US

Filing date 4 May 2006

Wipo publication date 9 November 2006

Acceptance publication date 17 September 2009

International Classifications

A61K 31/7125 (2006.01) - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

20 December 2007 PCT application entered the National Phase

  PCT publication WO2006/117400 Priority application(s): WO2006/117400

17 September 2009 Application Accepted

  Published as AU-B-2006243218

21 January 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006243223-The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy

2006243217-Phthalocyanine derivatives, process for their preparation, pharmaceutical compositions containing them, and their use